Iconovo AB, a developer of inhalable drugs based on proprietary inhalers and dry powder formulations, and Lonza, a healthcare development and manufacturing organization, have joined forces to develop spray-dried formulations of an intranasal biologic for Iconovo’s proprietary intranasal device ICOone Nasal. This project is the first in Iconovo’s strategic initiative to reformulate known pharmaceuticals and replace injections and oral treatments with inhalation. According to the agreement, ...